Exploring Immunotherapy Strategies in Endometrial Cancer

Program Description

In recent years, guideline updates have clarified the position of immune checkpoint inhibitors (ICIs) in the treatment of recurrent or metastatic endometrial cancer. This session will provide a foundational review of endometrial cancer, including its molecular subtypes, with a focused discussion on the critical role of biomarkers in guiding the use of ICIs. As essential members of the oncology care team, pharmacists can ensure the appropriate selection of ICI regimens and verify that a patient is receiving the correct ICI regimen based on their specific tumor characteristics. The faculty discussion will also address practical considerations pertaining to the management of immune-related adverse events (irAEs) and outline approaches to monitor for and manage the unique adverse events associated with immunotherapy to significantly reduce patients' risk of severe or life-threatening complications. By understanding the nuances of ICI therapy and navigating biomarker-driven decisions, pharmacists can play a proactive role in preventing severe toxicities and treatment interruptions.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the role of immune checkpoint inhibitors (ICIs) in the treatment of advanced or metastatic endometrial cancer, incorporating the latest clinical evidence and guideline-directed recommendations into practice
2. Apply biomarker results to inform treatment selection, escalation, and de-escalation strategies for patients with advanced or metastatic endometrial cancer, with an emphasis on immunotherapy-based regimens
3. Use evidence-based strategies for managing immune-related adverse events associated with ICI-based therapies for endometrial cancer, including dosing adjustments and therapy modifications
4. Provide key considerations when counseling patients with endometrial cancer about the initiation and course of ICI-based therapies, including toxicity expectations, treatment duration, and follow-up care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-400-H01-P. The activity is available for CE credit through December 5, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Erin Hickey Zacholski, PharmD, BCOP has the following relevant financial relationships with ineligible companies to disclose:

Consultant: RTI International, The American Journal of Managed Care, Verastem

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms